Abeona Therapeutics Q3 2020 Earnings Report
Key Takeaways
Abeona Therapeutics reported license and other revenues of $7.0 million for the third quarter of 2020, compared to zero revenues in the year-ago quarter. Net loss was $7.2 million for the third quarter of 2020, compared to net loss of $17.4 million for the comparable periods in 2019. Cash, cash equivalents, receivables and short-term investments totaled $103.9 million as of September 30, 2020, compared to $129.3 million as of December 31, 2019.
Cash, cash equivalents, receivables and short-term investments totaled $103.9 million as of September 30, 2020.
Net cash used in operating activities was $10.7 million for the third quarter of 2020.
License and other revenues for the third quarter of 2020 were $7.0 million, comprised of initial proceeds from the ABO-202 transaction.
Research and development expenses were $8.0 million for the third quarter of 2020.